Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

PAVmed (PAVM) EBIAT (2016 - 2025)

PAVmed has reported EBIAT over the past 5 years, most recently at -$1.3 million for Q4 2025.

  • For Q4 2025, EBIAT rose 91.51% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached -$975000.0, up 98.33%, while the annual FY2025 figure was $401000.0, 98.99% down from the prior year.
  • EBIAT for Q4 2025 was -$1.3 million at PAVmed, up from -$6.0 million in the prior quarter.
  • Over five years, EBIAT peaked at $18.6 million in Q1 2025 and troughed at -$34.7 million in Q4 2022.
  • A 5-year average of -$14.2 million and a median of -$14.9 million in 2024 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: tumbled 122.52% in 2022 and later soared 222.42% in 2025.
  • Year by year, EBIAT stood at -$17.2 million in 2021, then tumbled by 101.62% to -$34.7 million in 2022, then surged by 49.85% to -$17.4 million in 2023, then rose by 14.56% to -$14.9 million in 2024, then skyrocketed by 91.51% to -$1.3 million in 2025.
  • Business Quant data shows EBIAT for PAVM at -$1.3 million in Q4 2025, -$6.0 million in Q3 2025, and -$12.3 million in Q2 2025.